Superworth

Geron profit margin GERN

Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.

Net margin, 12 months
−33.1%
Operating margin, 12 months
−25.3%
Net margin on a year earlier
+20.5 pts
Peer median
11.6%

Over the twelve months to Jun 30, 2026, Geron kept −33.1% of its revenue as net profit, with an operating margin of −25.3%.

The median for 10 large drugmakers of a similar size is 11.6%.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025−45.4%−37.3%
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY20150.1%−1.5%
FY2014n/an/a
FY2013n/an/a
FY2012n/an/a
FY2011n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−33.1%+20.5 pts−25.3%
Q1 FY26−34.3%n/a−26.4%
Q4 FY25−45.4%n/a−37.3%
Q3 FY25−43.6%n/a−34.4%
Q2 FY25−53.5%n/a−47.1%
Q1 FY25n/an/an/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Geron's size, closest first, today.

CompanyProfit margin
GERNGeron−33.1%
COLLCollegium Pharmaceutical5.9%
ABUSArbutus Biopharma84.2%
CRMDCorMedix40.5%
ZVRAZevra Therapeutics42.8%
IRWDIronwood Pharmaceuticals33.4%
PBYIPuma Biotechnology11.6%
AMPHAmphastar Pharmaceuticals10.8%
ARVNArvinas2.9%
OMEROmerosn/m
PCRXPacira BioSciences2.0%
Peer median11.6%

Where Geron ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Geron

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.